Generation Bio’s Post

After ADC & CAR-T Now its time to bring them the CDCs (cell–drug conjugate) By combining living cells with therapeutics, cell–drug conjugates can enhance the functions of both components, especially in drug delivery and therapy applications. These conjugates can be engineered to persist in the bloodstream, exhibit chemotaxis, evade immune system detection, proliferate, and maintain or transform their cellular phenotypes. https://lnkd.in/g7QZUPVi

Harness the power of OncolinesProfiler’s™ sophisticated clustering analysis to map your compound’s IC50 fingerprint against the cellular activity of 213 anti-cancer therapeutics. Gain deep insights into your drug's biochemical action. Check out our capabilities and learn what we can do for you. https://ow.ly/X40x50QkHo2 #bioinformatics #comparativeprofiling

Komodo-dragon cathelicidin-inspired peptides are antibacterial against carbapenem-resistant Klebsiella pneumoniae Given the challenges of treating CRKP, identification of peptides with activity against it represents a promising avenue for further research. Given DRGN-6's similar level of activity to colistin, DRGN-6 is a promising template for the development of novel antimicrobial peptide-based therapeutics. https://lnkd.in/eysb3vWU

Imagine what you could do with 40% more cells after every isolation… Make it a reality with Akadeum's Alerion Microbubble Cell Separation System and our Human T Cell Leukopak Isolation Kit. Find out how Poseida Therapeutics is benefitting from the Alerion in this Case Study: https://hubs.li/Q02FVWDc0 #morecells #akadeum #celltherapy #cellisolation

Over the last few decades, researchers have made impressive strides in developing methods to overcome the delivery, stability, and specificity challenges of oligonucleotide therapeutics. However, we are yet to harness their full potential. How do ASO and siRNA therapies work? Find out in our blog: https://hubs.li/Q029FtFd0

Explore our most recent blog where we discuss how induced Pluripotent Stem Cells (iPSCs) can generate Hepatocyte Like Cells (HLCs) to be used as a pre-clinical model, increasing efficiency and efficacy of therapeutics reaching and succeeding through clinical trials. In this blog we use the real world case study of Alpha-1 antitrypsin deficiency (A1ATD) to showcase the potential of the OptiDIFF technology.

Obe-cel, an investigational therapy utilizing CD19 CAR T cells, aims to address the limitations in clinical effectiveness and safety observed with existing CD19 CAR T cell treatments. Autolus Therapeutics presents extended follow-up results and further data analysis from the key Phase Ib/II FELIX study of obecabtagene autoleucel (obe-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's ASCO 2024 Exclusive Coverage! https://lnkd.in/gE3gUFyM #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

DefiniGEN’s OptiDIFF technology platform enables the generation of iPSC-derived Alpha-1 antitrypsin deficiency disease modeled hepatocyte-like cells. Read our new blog post to: - Learn more about Alpha-1 antitrypsin deficiency, a monogenic inherited liver disease - Explore DefiniGEN’s capability to generate a patient panel which enables donor variance studies - Discover how DefiniGEN has created an accurate in-vitro preclinical model which aims to shorten the time taken in the drug discovery pipeline Visit our blog to discover how we can revolutionise the discovery and development of Alpha-1 antitrypsin deficiency therapeutics. https://bit.ly/48yxInR #A1AT #smallmolecules #genetherapy

Enhance your compound’s potential with clustering analysis via OncolinesProfiler™. Examine your compound’s cellular activity profile against the profiles of over 200 anti-cancer therapeutics. Identify or confirm target with our support. Discover more about collaborating to advance your program. https://ow.ly/vmHw50Rhi1L #Drugpositioning #comparativeanalysis #drugdiscovery

Colony-forming cell (CFC) assays have emerged as essential tools for addressing key questions regarding off-target hematotoxicity and expediting the submission of IND applications.  Discovery’s Gentest® Hematopoietic Colony-Forming Cell (CFC) Assay Services help preclinical researchers predict drug-induced anemia, neutropenia, and thrombocytopenia, as well as evaluate the effectiveness of certain drug candidates. Download our white paper to learn more:  https://lnkd.in/gzi_ntA7 We offer a comprehensive service menu of myeloid, erythroid, megakaryocytic, and blood cancer CFC assays.  Contact us today to learn how we can assist you in generating the CFC data you need.   #cfc #hematotoxicity #preclinicalresearch